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Abstract
Background: Small airway remodeling is an important cause of the airflow limitation in chronic obstructive
pulmonary disease (COPD). A large population of patients with COPD also have pulmonary hypertension. Krüppel-
like factor 5 (KLF5) is a zinc-finger transcription factor that contributes to tissue remodeling in cardiovascular
diseases. Here, we evaluate the possible involvement of KLF5 in the remodeling of small airways and pulmonary
vessels in COPD.
Methods: Lung tissues were obtained from 23 control never-smokers, 17 control ex-smokers and 24 ex-smokers
with COPD. The expression of KLF5 in the lung tissues was investigated by immunohistochemistry. We investigated
whether oxidative/nitrosative stress, which is a major cause of the pathogenesis in COPD, could augment the
production of KLF5. We examined the role of KLF5 in the stress-mediated tissue remodeling responses. We also
investigated the susceptibility of KLF5 expression to nitrosative stress using bronchial fibroblasts isolated from the
lung tissues.
Results: The expression of KLF5 was up-regulated in the small airways and pulmonary vessels of the COPD patients
and it was mainly expressed in bronchial fibroblasts and cells of the pulmonary vessels. The extent of the KLF5
expression in the small airway of the COPD group had a significant correlation with the severity of the airflow
limitation. Oxidative/nitrosative stress augmented the production of KLF5 in lung fibroblasts as well as the translocation
of KLF5 into the nuclei. Silencing of KLF5 suppressed the stress-augmented differentiation into myofibroblasts, the
release of collagens and metalloproteinases. Bronchial fibroblasts from the patients with COPD highly expressed KLF5
compared to those from the control subjects under basal condition and were more susceptible to the induction of KLF5
expression by nitrosative stress compared to those from the control subjects.
Conclusion: We provide the first evidence that the expression of KLF5 is up-regulated in small airways and pulmonary
vessels of patients with COPD and may be involved in the tissue remodeling of COPD.
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Background
The airflow limitation of chronic obstructive pulmonary
disease (COPD) patients is thought to be result from
two main pathological changes [1]. One is obstruction of
the small conducting airways by inflammatory mucous
exudates and airway wall remodeling, and the other is
the loss of elastic recoil because of emphysematous de-
struction of the pulmonary parenchyma [1–3]. Persistent
inflammation and oxidative/nitrosative stress cause re-
modeling of the small airways. Some previous reports
showed that the hyperproduction of growth factors such
as transforming growth factor-β1 (TGF-β1) and matrix
metalloproteinases (MMPs) could be involved in the re-
modeling of the small airways [4–8]. Other reports
showed that MMPs degrade extracellular matrix (ECM)
proteins, participate in ECM turnover, and promote sub-
sequent structural changes of the airways [9–11]. Al-
though the remodeling of small airways and pulmonary
vessels is apparent in COPD lungs and molecules such
as TGF-β1 and MMPs could be involved in the tissue re-
modeling, the precise mechanisms responsible for the
tissue remodeling remain poorly understood.
Oxidative stress has an important role in accelerating
the deterioration of lung function in COPD (1). Indeed,
the production of reactive oxygen species (ROS) such as
hydrogen peroxide (H2O2) is enhanced in the airways of
COPD patients [12–14]. Oxidative stress activates in-
flammatory genes, inactivates antiproteases and stimu-
lates mucus secretion [15, 16]. According to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines, many of these adverse effects are mediated
by reactive nitrogen species (RNS) such as peroxynitrite
(ONOO−). We previously demonstrated that the produc-
tion of RNS was augmented in the airways of COPD
patients compared to healthy subjects or asthmatic pa-
tients [17]. Both ROS and RNS are reported to stimulate
tissue remodeling through nuclear factor-κB (NF-κB) or
activator protein-1 (AP-1) in vitro [18–20]. However,
another transcription factor responsible for remodeling
of the small airways and pulmonary vessels in COPD
has not been elucidated yet.
KLF5 is a zing finger transcription factor that belongs
to the family of Krüppel-like factors and is implicated in
important biological functions, including embryonic
development, cellular differentiation and proliferation
[21–23]. Although a member of the KLF family such
as KLF2 is reported to be involved in the develop-
ment of various organs, especially lung development,
KLF5 is thought to be a key trnacription factor in tis-
sue remodeling among the KLF family [21–26]. The
expression of KLF5 is activated in cardiac fibroblasts
and contributes to tissue remodeling in cardiovascular
diseases [24, 25]. Although KLF5 is a key player in
the tissue remodeling of various organs [24–26], its
role in the remodeling of small airways and pulmon-
ary vessels in COPD remains unclear.
The present study was designed first to determine
whether the expression of KLF5 is up-regulated in the
lungs of COPD patients. Second, we investigated whether
ROS or RNS augment the expression and activation of
KLF5 in fibroblasts and whether KLF5 regulates the tissue
remodeling responses. Third, we examined the suscepti-
bility of KLF5 overexpression induced by nitrosative stress
in bronchial fibroblasts from COPD patients.
Methods
Preparation of human lung tissues
Twenty-three control never-smokers, 17 control ex-
smokers and 24 ex-smokers with COPD took part in the
study after giving written informed consent. COPD was
diagnosed according to the GOLD guidelines [1]. Be-
cause lung cancer is known to stimulate the expression
of KLF5, all the study subjects had had lung cancer and
peripheral lung tissues were obtained from the sub-
pleural parenchyma of the lobe resected at surgery,
avoiding areas involved by tumors. All subjects had
undergone surgical operation for lung cancer after re-
ceiving pulmonary function tests. The tissues were used
for immunohistostaining and the culture of bronchial
fibroblasts. All experiments in the current study were
approved by the ethics committee of Tohoku University
Graduate School of Medicine.
Immunochemical detection of KLF5 and prolyl
4-hydroxylase β (P4HB)
The lung tissues from the control never-smokers, con-
trol ex-smokers and ex-smokers with COPD were used
in the immunohistological examination of KLF5 and
P4HB. Briefly, after fixation with 4 % paraformaldehyde
for 30 min, the tissues were blocked with 1 % skim milk
for 30 min and rinsed. The samples were incubated with
rabbit polyclonal anti-KLF5 antibody (1:1000 dilution,
Abcam, Cambridge, UK), plus mouse monoclonal anti-
P4HB antibody (1:400 dilution, Novus, Littleton, CO), or
non-specific polyclonal rabbit IgG as a negative control
at 4 °C overnight. After washing for immunohistochem-
istry, the samples were treated with the goat anti-rabbit
IgG horseradish peroxidase labeled polymer-conjugated
secondary antibody (Santa Cruz Biotechnology, Dallas,
TX) for 60 min and 3,3′-diaminobenzidine (Nichirei
Biosciences Inc, Tokyo, Japan) was used to visualize
labeling. The samples were viewed by microscopy (BX53-
33-SDO, Olympus, Tokyo, Japan) and photographed with
a digital camera (DP71-SET, Olympus, Tokyo, Japan). For
immunofluorescent staining, the samples were incubated
with goat anti-rabbit IgG conjugated with fluorescein iso-
thiocyanate (FITC, 1:1000 dilution, Abcam) for 60 min at
room temperature. Then, after washing again, they were
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incubated with goat anti-mouse IgG conjugated with
Dylight 650 (1:50 dilution, Abcam) for 60 min. After
washing, they were stained with Fluoromount-G contain-
ing DAPI (Southern Biotech, Birmingham, AL) and then
viewed and photographed using a multiphoton confocal
LSM 780 NLO microscope system (Carl Zeiss, Jena,
Germany).
Measurement of KLF5 positive cells
The KLF5-positive area was quantified as follows. Three
areas per each lung specimen were randomly chosen.
One area usually contained a couple of peripheral air-
ways. Among these areas, five random airways were
chosen by two investigators without any prior knowledge
of the background of the subjects. The area of KLF5 in
small airways was defined as the submucosal area of
KLF5-positive cells standardized by the length of the air-
way basement membrane. The area of KLF5 in pulmon-
ary small vessels was also defined as the vascular wall
area of KLF5-positive cells standardized by the lumen
diameter of the pulmonary vessels. The area and the
length were measured using Image J (National Institutes
of Health, Frederick, MD).
Cell culture
Human fetal lung fibroblasts (HFL-1) were obtained
from the American Type Culture Collection (Rockville,
MD). Four different strains of adult fibroblasts were ob-
tained from lung tissues resected by surgical operation
from COPD or non-COPD patients with lung cancer in
our institution. The HFL-1 and adult cells were cultured
on tissue culture dishes with Dulbecco’s Modified Eagle’s
Medium (DMEM, Invitrogen Life Technologies, Grand
Island, NY) supplemented with 10 % fetal calf serum
(FCS, Invitrogen Life Technologies), 100 unit/ml penicil-
lin, and 100 μg/ml streptomycin. Cells were cultured at
37 °C in a humidified atmosphere of 5 % CO2 and pas-
saged. HFL-1 cells were used between the 16th and 18th
passages. The adult bronchial fibroblasts from the study
subjects were used between the 4th-5th passages.
Western blotting
Cells were seeded in 60 mm dishes at a density of
1 × 105 /ml. At 90 % confluence, the cells were treated with
various concentrations of H2O2 (Wako, Osaka, Japan) or
ONOO− (Calbiochem, La Jolla, CA). To obtain the nuclear
fractions, a Nuclear Extraction Kit (Active Motif, Carlsbad,
CA) was used according to the manufacturer’s instructions.
The cells were washed with ice-cold PBS and homogenized
in cell lysis buffer. Equal amounts of protein were loaded
and separated by electrophoresis on 12 % SDS polyacryl-
amide gels. The separated proteins were transferred to a
polyvinylidene difluoride membrane (Bio-Rad Laboratories,
Hercules, CA). The following antibodies were used for
detection of the target proteins: rabbit polyclonal anti-
KLF5 antibody (1:1000 dilution, Abcam), mouse monoclo-
nal anti-β-actin antibody (1:4000 dilution, Sigma-Aldrich,
St. Louis, MO), mouse monoclonal anti-lamin A/C anti-
body (1:400 dilution, Santa Cruz Biotechnology, Dallas,
TX), mouse monoclonal anti-α-SMA (1:5000 dilution,
Sigma-Aldrich). Bound antibodies were visualized using
the appropriate peroxidase-conjugated secondary anti-
bodies and enhanced chemiluminescence (GE Healthcare
Life Sciences, Buckinghamshire, UK) with a chemilumines-
cene imaging system (LAS-4000 mini, Fujifilm, Tokyo,
Japan). Band intensity was quantified by densitometry
(Quantity One, Bio-Rad Laboratories).
Silencing of KLF5
Small interfering RNA (siRNA) for KLF5 (ON-TARGET-
plus SMART pool siRNA) and control siRNA (ON-TAR-
GET plus Non-targeting Pool) were purchased from
Darmacon (Lafayette, CO). Using Lipofectamine RNAi-
MAX (Invitrogen Life Technologies), the siRNA was
transfected into HFL-1 cells plated in 60 mm dishes at a
final concentration of 5 nM in 5 ml of 10 % FCS DMEM
without antibiotics. The infected cells were used for the
experiments of α-smooth muscle actin production and
release of collagen and MMPs.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
Total RNA was isolated from homogenized HFL-1 cells
using RNeasy kit (Qiagen, Valencia, CA). RNA samples
were reverse-transcribed with a High Capacity RNA-to-
cDNA Kit (Applied Biosystems, Forster City, CA). qRT-
PCR was performed using Power SYBR Green PCR
Master Mix (Applied Biosystems Life Technologies,
Warrington, UK), and was carried out on Step One Plus
(Applied Biosystems). The data were standardized by
GAPDH. The primer sequences were as follows: KLF5,
5′-ACGACGCATCCACTACTGCG-3′ and 5′-GTGAG
TCCTCAGGTGAGCTT-3′; GAPDH, 5′-GCACCGTCA
AGGCTGAGAAC-3′ and 5′-TGGTGAAGACGCCAGT
GGA-3′.
Collagen assay
The amounts of collagen in the supernatants were mea-
sured using the Sircol Collagen Assay kit (Biocolor Ltd.,
Belfast, Northern Ireland) according to the manufac-
turer’s protocol.
Zymogram
Supernatants from the cell cultures (500 μl per culture
condition) were concentrated 10-fold by precipitation
with cold ethanol and re-suspended in 50 μl double-
distilled water (ddW). The samples were solubilized in
SDS-PAGE sample buffer without 2-mercaptoethanol.
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Equal amounts of samples (20 μl) were separated in
10 % SDS–PAGE containing gelatin (1 mg/ml) under
non-reducing conditions. After electrophoresis, the gels
were soaked in zymogram renaturing buffer (Invitrogen,
Carlsbad, CA) for 60 min and incubated in zymogram
developing buffer (Invitrogen) for 18 h at 37 °C. The gels
were stained with 0.4 % Coomassie blue (Nacalai Tesque,
Kyoto, Japan) for 15 min at room temperature and rapidly
destained with destaining buffer (30 % methanol and 10 %
acetic acid in ddW). Zones of proteolysis appeared as clear
white bands against a blue background and were scanned
using a Chemi DOC XRS system (Bio-Rad Laboratories).
Band intensity was quantified using Quantity One soft-
ware (Bio-Rad Laboratories).
Statistical analysis
Data were expressed as means ± standard deviation (SD).
A linear regression analysis was done using the method of
least squares. Significance was analyzed by the Spearman’s
rank test. Experiments with multiple comparisons were
evaluated by one way analysis of variance (ANOVA)
followed by Scheffé’s test to adjust for multiple compari-
sons. Graphpad Prism 5 (GraphPad Software, Inc., San
Diego, CA) and StatView 4.54 (Abacus. Concepts, Inc.,
Berkeley, CA) were used for all analyses. Probability values
of less than 0.05 were considered significant.
Results
Characteristics of the study subjects
The characteristics of the study subjects are listed in
Table 1. Twenty-three control never-smokers, 17 control
ex-smokers and 24 ex-smokers with COPD took part in
the study. In the control never smoker group, more fe-
male subjects were included in this study compared to
the other groups. There was no statistical difference in
the parameters among the three groups except for lung
function.
Analysis of KLF5 expression in the small airways and
pulmonary vessels
We investigated KLF5 expression in the lungs by immu-
nohistochemistry. KLF5 was mainly expressed in the
submucosa of the small airways (Fig. 1a). The KLF5-
immunopositive area in the COPD group was significantly
increased compared to that in the two control groups
(Fig. 1a and b). The cells of pulmonary vessels from the
COPD patients also strongly expressed KLF5 compared to
those from the control subjects (Fig. 2a and b). To identify
the cell types that expressed KLF5, we conducted double
immunofluorescent staining. KLF5-immunopositive
cells in the small airways also expressed P4HB, which
is known to be a marker of fibroblasts (Fig. 3). The
values of the KLF5-immunopositive areas in the small air-
ways of the COPD group were significantly correlated with
those of forced expiratory volume in 1 s (FEV1) %predicted
(r= −0.91, p < 0.01; Fig. 4a) and forced vital capacity (FVC)
%predicted (r =−0.75, p < 0.01; Fig. 4b), but not with the
diffusing capacity of the lung for carbon monoxide/alveolar
volume (DLCO/VA) %predicted (Fig. 4c).
H2O2 and ONOO
− augment production and activation of
KLF5 in HFL-1 cells
To elucidate whether ROS and RNS augment the pro-
duction of KLF5 in lung fibroblasts, HFL-1 were incu-
bated with various concentrations of either H2O2 or
ONOO− and then the production of KLF5 was assessed
by immunoblotting. H2O2 significantly augmented the
production of KLF5 in a concentration-dependent man-
ner compared to the control (at 10−6 M, 2.2-fold in-
crease, p < 0.01, Fig. 5a). The production of KLF5 was
significantly increased at 24 and 48 h after treatment
with 10−6 M H2O2 (Fig. 5b). Similarly, ONOO
− signifi-
cantly augmented the production of KLF5 compared to
control (at 10−7 M, 1.9-fold increase, p < 0.01, Fig. 5c),
and KLF5 was significantly increased at 24, 48 and 72 h
after treatment with 10−7 M ONOO− (Fig. 5d). Further-
more, we investigated the translocation of KLF5 into the
nucleus to determine whether KLF5 was activated by
ROS and RNS. After treatment with 10−6 M H2O2, the
amount of KLF5 in the nuclear fraction was significantly
increased at 4 h compared to control (at 4 h, 2.3-fold in-
crease, p < 0.05, Fig. 5e) as well as ONOO− (at 10−7 M,
4 h, 2.7-fold increase, p < 0.01, Fig. 5f ).
Effects of KLF5 silencing on the H2O2 or ONOO
−-augmented
production of α-SMA and release of collagens and MMPs
To investigate whether KLF5 regulates the differenti-
ation of fibroblasts into myofibroblast, the effect of
Table 1 Characteristics of the subjects in the lung tissue study
Control never-
smokers
Control ex-
smokers
COPD ex-
smokers
Subjects n 23 17 24
Male sex, % 30.4 82.4 87.5
Age, y 66.3 ± 9 65.3 ± 10 70.8 ± 7
Smoking status, pack-y 0 42.2 ± 20 49.0 ± 28
FEV1, L 2.41 ± 0.60 2.55 ± 0.47 1.83 ± 0.53
**
FEV1 %predicted, % 112 ± 16 92.5 ± 8.0
* 72.7 ± 18*, **
FVC, L 3.05 ± 0.72 3.35 ± 0.66* 3.04 ± 0.74**
FVC %predicted, % 114 ± 15 98.8 ± 9.0 96.8 ± 17*
FEV1/FVC, % 79.2 ± 4.4 76.3 ± 4.1 59.6 ± 8.3
*, **
DLCO/VA %predicted, %
a 96.1 ± 14 89.7 ± 15 79.9 ± 22*
Data are presented as mean ± SD. FEV1 = forced expiratory volume in 1 s;
FVC = forced vital capacity; DLCO = diffusing capacity of the lung for carbon
monoxide; VA = alveolar volume
a:DLCO/VA are 23 healthy never-smokers, 16 healthy ex-smokers, and 22 COPD
ex-smokers. *: p < 0.05 compared to control never smokers. **: p < 0.05
compared to control ex-smokers
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KLF5 silencing on the H2O2 or ONOO
−-augmented pro-
duction of α-SMA was evaluated. The target siRNA di-
minished the mRNA expression and reduced the protein
production of KLF5 (Fig. 6a and b). The siRNA signifi-
cantly abrogated the H2O2 or ONOO
−-augmented pro-
duction of α-SMA (p < 0.01, Fig. 6c and d). The effect of
KLF5 silencing on the release of collagen was also evalu-
ated. The siRNA significantly abrogated the ONOO−-aug-
mented release of collagen (p < 0.01, Fig. 6e). We
investigated whether KLF5 regulated the fibroblast-
mediated release of MMPs. The siRNA significantly abro-
gated the ONOO− -augmented release of latent MMP-9
(p < 0.01, Fig. 7a and b), active MMP-9 (p < 0.01, Fig. 7a
and c), latent MMP-2 (p < 0.01, Fig. 7a and d) and active
MMP-2 (p < 0.01, Fig. 7a and e).
Production of KLF5 in bronchial fibroblasts from the
patients with COPD
To confirm that bronchial fibroblasts from the COPD
patients express more KLF5, we used cells from the con-
trol subjects and the age-matched patients with COPD
(Table 2). Under the basal condition, the COPD cells
showed significantly increased the production of KLF5
compared to those of the control subjects (p < 0.01,
Fig. 8a). In the COPD cells, ONOO− markedly stimu-
lated production of KLF5 (p < 0.01, Fig 8b) and the fold
changes of KLF5 in the COPD group significantly in-
creased compared to those of the control never-
smoker group (p < 0.05, Fig. 8b), suggesting that
COPD bronchial fibroblasts were more susceptible to
KLF5 expression induced by nitrosative stress com-
pared to control cells.
Discussion
In the present study, we demonstrated that the expres-
sion of KLF5 was up-regulated in the small airways and
pulmonary small vessels of patients with COPD com-
pared to those of control subjects, and that KLF5 was
mainly expressed in the submucosal fibroblasts and cells
of the pulmonary vessels in the patients with COPD.
The expression levels in the small airways were signifi-
cantly correlated with the severity of the airflow
Fig. 1 Semiquantitative measurement of Krüppel-like factor 5 (KLF5) production in the small airways by immunohistochemical staining. Lung
tissues were obtained from control subjects that never or previously smoked and from former smokers with COPD. The localization of KLF5 in the
lung tissues was investigated by immunostaining. Representative photographs of the immunoreactivity of KLF5 in the small airways are shown
(original magnification × 200 for upper panels and left middle panel, × 400 for right middle panel; scale bars = 100 μm) (a). A negative control
sample was provided to replace a non-specific polyclonal rabbit IgG antibody instead of the primary antibody on the lung tissue specimens of
the patients with COPD. Arrow heads indicate KLF5-immunopositive cells. The immunopositive area of KLF5 in the small airways was quantified
using Image J (b). **p < 0.01 versus control never smoker, ††p < 0.01 versus control ex-smoker
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Fig. 2 Semiquantitative measurement of KLF5 production in the pulmonary vessels by immunohistochemical staining. The localization of KLF5 in
the lung tissues was investigated by immunostaining. Representative photographs of the immunoreactivity of KLF5 in the pulmonary vessels are
shown (original magnification × 200 for upper panels and left lower panel, × 400 for right lower panel; scale bars = 100 μm) (a). A negative control
sample was provided to replace the non-specific polyclonal rabbit IgG antibody instead of the primary antibody for the lung tissue specimens of the
patients with COPD. Arrow heads indicate KLF5-immunopositive cells. The immunopositive area of KLF5 in the pulmonary vessels was quantified using
Image J (b). **p < 0.01 versus control never smoker, ††p < 0.01 versus control ex-smoker
Fig. 3 Immunoreactivity of KLF5 in the bronchial fibroblasts. To determine the cell types that expressed KLF5, double immunostaining for KLF5
and prolyl 4-hydroxylase β (P4HB) was carried out. P4HB is a marker of fibroblasts. Representative photographs of the immunoreactivity of KLF5
(green) and P4HB (red) are shown (original magnification × 200 for all panels; scale bars = 100 μm). A negative control sample was provided to
replace the non-specific polyclonal rabbit IgG antibody instead of the primary antibody for the lung tissue specimens of the patients with COPD.
DAPI: 4′,6-diamidino-2-phenylindole; HE: hematoxylin-eosin staining
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limitation. The in vitro study demonstrated that oxida-
tive/nitrosative stress, which is a major cause of the
pathogenesis in COPD, augmented the expression of
KLF5 in the human lung fibroblasts as well as the trans-
location of KLF5 into the nuclei. Silencing of KLF5 sig-
nificantly suppressed production of α-SMA, the release
of collagen and MMPs from lung fibroblasts. The COPD
bronchial fibroblasts expressed more KLF5 compared to
those from the control subjects. In addition, the COPD
fibroblasts had more susceptibility to KLF5 overexpres-
sion induced by nitrosative stress compare to that in
control never-smokers. These results suggest that KLF5
may play a pivotal role in the tissue remodeling in
patients with COPD.
Airway obstruction is commonly observed in the small
airways of patients with COPD, and it is thought to be a
major cause of the airflow limitation in patients with
COPD as well as pulmonary emphysema [3]. Although
some previous reports suggested that hyperproduction
of TGF-β1 released from inflammatory cells could be in-
volved in the airway remodeling [4–6], the possible
mechanisms underlying small airway remodeling in
COPD has remained poorly understood. KLF2, one of
KLF family is considered to be involved in lung develop-
ment. Among KLF families, KLF5 is reported to regulate
embryonic development, cellular differentiation and
proliferation [21–23]. Recently, it was reported that
KLF5 is highly expressed in cardiac fibroblasts under
pressure overload and contributes to the development of
cardiac hypertrophy and fibrosis through the release of
several growth factors including TGF-β, platelet-derived
growth factor (PDGF), and insulin-like growth factors
(IGF) [24, 25]. However, whether the expression of KLF5
occurs in the normal respiratory system as well as under
pathological conditions is not known. In the current
study, we first found increased expression of KLF5 in
the fibroblasts of the small airways in the patients with
COPD compared to the control subjects. Because KLF5
is thought to regulate tissue remodeling and fibrosis in
other organs, KLF5 may be involved in the remodeling
of small airways.
Interestingly, we found that the cells of the pulmonary
arterial wall in the patients with COPD strongly
expressed KLF5 compared to those of the control sub-
jects, as shown in Fig. 2. Because the expression of KLF5
is reportedly up-regulated in the cells of arteries in the
systemic circulation and regulates vascular remodeling
[25], the strong expression of KLF5 in the pulmonary
vessels of COPD patients may be involved in the remod-
eling of the pulmonary vessels. Recent findings have
suggested that pulmonary hypertension (PH) plays a key
role in the pathophysiology of COPD [27]. This
Fig. 4 Relationship between the immunopositive area for KLF5 in the small airways and lung function. The relationship between the KLF5-positive area
in the small airways and the values of FEV1 %predicted (a), FVC %predicted (b), and DLCO/VA %predicted (c) was investigated in the COPD group. r is
the correlation coefficient; the lines and p values correspond to the fitted regression equation. FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; DLCO: diffusing capacity of the lung for carbon monoxide; VA: alveolar volume; N.S.: not significant
Abe et al. Respiratory Research  (2016) 17:7 Page 7 of 13
Fig. 5 Effect of hydrogen peroxide (H2O2) or peroxynitrite (ONOO
−) on KLF5 production and translocation into the nucleus in human fetal lung
fibroblasts (HFL-1). Production of KLF5 was analyzed by immunoblotting. HFL-1 cells were treated with various concentrations of H2O2 for 24 h (a)
and with 10−6 M H2O2 for various durations (b) as well as ONOO
− for 24 h (c) and 10−7 M ONOO− for various durations (d). Each band intensity
of KLF5 was standardized by that of β-actin. Translocation of KLF5 into the nucleus was also analyzed by immunoblotting. The cells were treated with
10−6 M H2O2 (e) or 10
−7 M ONOO− (f) and the nuclear fraction was harvested at various time points. Each band intensity of KLF5 was standardized by
that of lamin A/C. All values are expressed as mean ± SD for 4–7 separate experiments. *p < 0.05, **p < 0.01 versus control group
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hypothesis is supported by the observation that a large
proportion of patients with COPD also have PH, with
percentages ranging from 30 to 70 % [28], and that even
smokers who do not suffer from COPD can develop pul-
monary vascular remodeling [29]. A recent study also
showed that the expression levels of KLF5 in pulmonary
artery smooth muscle cells from patients with PH are
higher than in those from healthy subjects [30]. These
findings suggest that KLF5 could become a therapeutic
target in COPD patients with PH.
We demonstrated in the present study that the degree
of expression of KLF5 had a significantly positive correl-
ation with the severity of the airflow limitation. Both ob-
struction of the small airways and easy collapsibility due
to the loss of elastic recoil are believed to contribute to
the airflow limitation in COPD. In this study, we could
Fig. 6 Effects of KLF5 silencing by siRNA on the H2O2 or ONOO
−-augmented the production of α-smooth muscle actin (α-SMA) and release of
collagens. Effects of siRNA for KLF5 on the gene expression and the protein production were confirmed by quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) for 24 h after transfection (a) and immunoblotting for 72 h (b). Effects of KLF5 silencing on the H2O2 (c) or
the ONOO− (d)-augmented production of α-SMA were analyzed by immunoblotting. Each band intensity was analyzed by Quantity One. Effect
of KLF5 silencing on the ONOO−-augmented release of collagens was analyzed (e). All values are expressed as mean ± SD for 4 separate experiments.
**p < 0.01 versus vehicle-pretreated vehicle-exposed group. †p < 0.05, ††p < 0.01 versus vehicle-pretreated H2O2 or ONOO
−-exposed group
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not evaluate the role of KLF5 in the loss of elastic recoil
in the pulmonary parenchyma. However, Hogg JC et al.
showed that the progression of COPD from mild to very
severe was most strongly associated with thickening of
the small airway walls and each of their compartments
by a repair or remodeling process [3]. Furthermore,
McDonough JE et al. demonstrated that the obstruction
and disappearance of small conducting airways could
initiate the onset of emphysematous destruction in
COPD [31]. Because the COPD of the patients who
enrolled in this study was relatively mild to moderate,
the obstruction of the small airways might have had a
stronger effect on the airflow limitation than the loss of
elastic recoil.
We found that ROS and RNS are potent inducers
and activators of KLF5 in human lung fibroblasts.
KLF5 expression is induced by various stimuli in
other cells. In vascular smooth muscle cells, KLF5
was reported to be up-regulated by angiotensin II via
endogenous ROS [32, 33]. In addition, exogenous H2O2
augmented the mRNA expression of KLF5 in vascular
smooth muscle cells [32]. These finding support our
current data. The mechanism for the induction and acti-
vation of KLF5 by ROS and RNS should be clarified and
the signal transduction for the regulation of KLF5 gene
should be addressed in greater detail.
Fig. 7 Effects of KLF5 silencing by siRNA on the ONOO−-augmented release of matrix metalloproteinases (MMPs). Effects of KLF5 silencing on the
ONOO−-augmented release of MMP-9 and MMP-2 were investigated by gelatin zymography (a). After silencing, the infected cells were incubated
with 10−7 M ONOO− (filled bars) or vehicles (open bars) for 24 h. Latent form of MMP-9 (a and b), active form of MMP-9 (a and c), latent form of
MMP-2 (a and d), and active form of MMP-2 were evaluated. Each band intensity was analyzed by Quantity One. All values are expressed as
mean ± SD for 4 separate experiments. **p < 0.01 versus vehicle-pretreated vehicle-exposed group. †p < 0.05, ††p < 0.01 versus vehicle-pretreated
ONOO−-exposed group
Table 2 Characteristics of the subjects in the bronchial fibroblasts
study
Control never-
smokers
Control ex-
smokers
COPD ex-
smokers
Subjects n 4 4 4
Age, y 61.5 ± 15 70.8 ± 3 67.0 ± 3
FEV1, L 2.86 ± 0.93 2.65 ± 0.84 2.42 ± 0.51
FEV1 %predicted, % 110 ± 16 112 ± 18 83.6 ± 17
*,**
FVC, L 3.46 ± 0.92 3.24 ± 1.2 3.72 ± 0.66
FEV1/FVC, % 81.8 ± 4.5 77.6 ± 7.9 63.8 ± 8.3
*,**
Data are presented as mean ± SD. FEV1 = forced expiratory volume in 1 s;
FVC = forced vital capacity
*: p < 0.05 compared to control never smokers. **: p < 0.05 compared to
control ex-smokers
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Oxidative stress is an important mechanism that accel-
erates the deterioration of lung function in COPD [16].
Many reports showed that oxidative stress activates in-
flammatory genes, inactivates antiproteases and stimu-
lates mucus secretion [15, 16]. Nitrosative stress is
induced by RNS such as ONOO−, and we first found
that RNS production was enhanced in the airways of
COPD patients [17]. According to the GOLD guidelines,
RNS are considered to mediate many of the adverse
effects of oxidative stress. Although endogenous or
exogenously produced ROS and RNS have been clearly
shown to possess many adverse effects involved in the
pathogenesis of COPD, they might affect the develop-
ment of airway remodeling via KLF5 pathway.
We clearly showed that KLF5 regulated the tissue re-
modeling responses including myofibroblast differenti-
ation, and the release of collagen and MMPs from
human lung fibroblasts, since the silencing of KLF5 gene
abrogated the oxidative/nitrosative stress-augmented tis-
sue remodeling responses. Previous reports showed that
Fig. 8 Production of KLF5 in adult human bronchial fibroblasts and effects of ONOO− on production of KLF5 in adult cells. Bronchial fibroblasts
were isolated from the lungs of the subjects in each study group. Four different strains of bronchial fibroblasts in each group were obtained. The
amounts of KLF5 were analyzed by immunoblotting (a). **p < 0.01 versus control never-smoker, ††p < 0.01 versus control ex-smoker. The fibroblasts
were treated with 10−6 M ONOO− for 24 h. The production of KLF5 was analyzed by immunoblotting (b). Each band intensity of KLF5 was standardized
by that of β-actin. *p < 0.05, **p < 0.01. All values are expressed as mean ± SD. CNS = Control never-smoker; CES = Control ex-smoker,
COPD = COPD ex-smoker
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KLF5 regulated tissue remodeling through the release
of several growth factors such as TGF, PDGF, and
IGF [24, 25]. Furthermore, it has been reported that
the overexpression of KLF5 caused gelatin degrad-
ation by stimulating the promoter activity of MMP-9
without affecting chondrocyte differentiation or vascu-
lar endothelial growth factor expression in cultured
chondrogenic cells [34]. In addition, KLF5 dysfunction
by genetic heterodeficiency or RNA interference was
confirmed to cause a reduction of MMP-9 expression in
cultured chondrogenic cells [34]. These findings support
our current data. Our results suggest that KLF5 is a key
regulator of tissue remodeling and closely involved in the
pathogenesis of COPD.
In this study, we confirmed the overexpression of
KLF5 in bronchial fibroblasts from the COPD patients
compared to that from the control subjects under the
basal condition. The cells from the COPD patients were
more susceptible to KLF5 overexpression induced by
nitrosative stress. In our previous reports, bronchial fi-
broblasts from asthmatic mice showed a profibrotic
property compared to those from control mice [35], and
the lung fibroblasts from severe COPD patients showed
impaired tissue repair function [36]. Furthermore, we
previously demonstrated that bronchial fibroblasts from
asthmatic patients released more MMPs when the cells
were stimulated by ligand for toll-like receptor 3 [37].
Little is known about whether there are differences in
the susceptibility to stimuli which may possibly influence
the development and progression of the pathological
changes observed in the lungs of COPD paients.
There are several limitations in this study. First, both
ROS and RNS are generally reported to stimulate tissue
remodeling through NF-κB and/or AP-1. It is well
known that, when these transcription factors are acti-
vated, tissue remodeling is accelerated via TGF-β and
MMP production [18, 37]. We did not investigate the
crosstalk between KLF5 and other transcription factors
in the current study. Second, Takeda and coworkers
demonstrated that cardiac pressure overload stimulated
the expression of KLF5 in cardiac fibroblasts and that
IGF-1 released from activated fibroblasts caused hyper-
trophy of the myocardium in vivo through crosstalk be-
tween myocardial fibroblasts and cardiac myocytes [24].
In the present study, we did not evaluate cell-cell inter-
actions such as those between airway epithelial cells and
fibroblasts. Further studies are needed to clarify whether
KLF5 can interact with other transcription factors and
other types of cells in the airways.
Conclusions
The current study showed that the expression of KLF5
was enhanced in the peripheral airways and pulmonary
vessels of patients with COPD compared to those of the
control subjects. KLF5 was mainly expressed in the sub-
mucosal fibroblasts of small airways and the cells of pul-
monary vessels. The expression levels were well correlated
with the severity of the airflow limitation in COPD. Oxi-
dative/nitrosative stress augmented the expression and ac-
tivation of KLF5 in the human lung fibroblasts and KLF5
could regulate the fibroblast-mediated tissue remodeling.
Bronchial fibroblasts from COPD patients were more sus-
ceptible to KLF5 overexpression against nitrosative stress.
Our data suggest a possible mechanism in the KLF5-
regulated tissue remodeling in the small airways and pul-
monary vessels of COPD. Modulation of this pathway
may have therapeutic potential for the tissue remodeling
observed in patients with COPD.
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